Centre Of Research Excellence In Indigenous Children's Healthy EARs (ICHEAR)
Funder
National Health and Medical Research Council
Funding Amount
$2,615,897.00
Summary
The overwhelming burden of otitis media (middle ear inflammation, OM) and the consequences of hearing loss on social and educational outcomes in Indigenous children are indisputable. Our CRE_ICHEAR is a multidisciplinary group of Australia’s experts in OM research, policy and practice guidelines. The CRE will derive better value in terms of discovery, translation and sustainability. Increased Indigenous leadership will raise awareness and advocacy, with greater efficiency of research translation
A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
A Randomised Open-label Study Comparing The Safety And Efficacy Of Two Alternative Treatment Options In The Management Of HIV-1 Infected Participants Who Have Virologically Failed A Standard First-line Combination ART Regimen
Funder
National Health and Medical Research Council
Funding Amount
$457,676.00
Summary
For the past decade there has been an unprecedented international effort to provide access to care for all HIV-infected people as a basic human right. Most of these people are treated with a simple combination of drugs that are well proven to control HIV. However, what to do when this first drug combination stops working is unknown. This study aims to fill that knowledge gap so that patients failing the first drug combination can be offered a second combination with a maximal chance of success.
RV3 Rotavirus Vaccine: A Human Neonatal Rotavirus Vaccine For The Asia-Pacific Region
Funder
National Health and Medical Research Council
Funding Amount
$2,264,330.00
Summary
Rotavirus infection is the leading cause of severe dehydrating gastroenteritis responsible for ~600,000 deaths per year in children <5 years of age worldwide. In this proposal we outline plans for the development of a human neonatal rotavirus vaccine in Indonesia. The goal is a safe and effective rotavirus vaccine affordable for children within the Asia-Pacific region and worldwide.
Community Treatment Intervention With Ivermectin To Reduce The Prevalence Of Scabies And Strongyloides
Funder
National Health and Medical Research Council
Funding Amount
$109,046.00
Summary
Scabies and strongyloides are endemic in many remote East Arnhem Aboriginal communities. To reduce the prevalence of these parasitic infections a community treatment intervention will be undertaken using the drug Ivermectin. The introduction of this innovative drug treatment regime for both scabies and strongyloides will be a first in Australia.
Treatment And Prevention Of HIV And Sexually Transmitted Infections
Funder
National Health and Medical Research Council
Funding Amount
$772,490.00
Summary
My research will use statistical and mathematical models to answer questions in the prevention and treatment of infectious diseases. I will assess long-term outcomes in HIV positive patients, including developing risk prediction models to improve patients monitoring. I will look at strategies to improve antiretroviral treatment in developing countries in Asia. And I will identify optimal preventions strategies to reduce rates of sexually transmitted infections.
An In Depth Analysis Of Clinical And Virological Outcomes Of 2 Strategies For The Antiretroviral Salvage Of First-line Regimen Virological Failure For HIV-1 Infection Tested In An Australian-led Randomised, International, Multi-centre Clinical Trial
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The recently completed Australian-led SECOND-LINE trial is the first high quality study to provide reliable evidence for policy recommendations for the composition of anti-HIV drug cocktails after standard initial treatment has failed. This award will support the researcher in further refining our understanding of how to manage second-line therapy including proposals to test the use of low-cost technologies for application in resource-limited settings where the majority of people with HIV live.
Understanding, Detecting, Monitoring And Treating Brain Dysfunctions Due To Chronic Immune Diseases
Funder
National Health and Medical Research Council
Funding Amount
$415,219.00
Summary
The role of immune burdens on the brain of middle-aged persons is not well understood. For example the combined brain effects of HIV and cardio-vascular diseases are unknown. Our research is about better understanding those processes using advanced neuropsychology and brain imaging methods. It is also about developing new instruments to detect problems as early as possible, to monitor them accurately and to better treat them in Australia and the Asia-Pacific region.
A Study Of Factors That May Influence The Neurocognitive Health Of HIV+ Populations: For Better- Early Antiretroviral Therapy? For Worse- Cardiovascular Risk Factors And Disease?
Funder
National Health and Medical Research Council
Funding Amount
$362,123.00
Summary
Cognitive health is of primary importance to HIV affected communities. Recently high blood pressure and high cholesterol have been associated with poor cognitive performance in middle aged HIV+ patients. We plan to study whether HIV+ patients with cardiovascular risk factors have faster and more frequent cognitive decline than HIV+ and HIV- patients without these risk factors. In another study we plan to determine the potential benefits of early versus deferred HIV antiretroviral therapy upon ne ....Cognitive health is of primary importance to HIV affected communities. Recently high blood pressure and high cholesterol have been associated with poor cognitive performance in middle aged HIV+ patients. We plan to study whether HIV+ patients with cardiovascular risk factors have faster and more frequent cognitive decline than HIV+ and HIV- patients without these risk factors. In another study we plan to determine the potential benefits of early versus deferred HIV antiretroviral therapy upon neurocognitive performance.Read moreRead less